Due to technical issues, the Customer Support line is currently unavailable. Please use the live chat or email communication.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.00p -0.54% 1,468.50p 1,468.50p 1,469.00p 1,476.50p 1,466.00p 1,470.00p 370,600 13:37:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,845.5 612.4 59.6 25.1 12,848.06

Smith & Nephew Plc Acquisition

17/04/2019 2:05pm

UK Regulatory (RNS & others)


Smith & Nephew (LSE:SN.)
Historical Stock Chart

1 Month : From Mar 2019 to Apr 2019

Click Here for more Smith & Nephew Charts.

TIDMSN.

RNS Number : 5229W

Smith & Nephew Plc

17 April 2019

Smith & Nephew Completes Acquisition of Osiris Therapeutics, Inc.

17 April 2019

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million. Osiris is a fast growing company delivering regenerative medicine products including skin, bone graft and articular cartilage substitutes.

The acquisition is expected to accelerate growth from Smith & Nephew's Advanced Wound Management franchise.

Osiris delivered revenue of $142.8 million for the year ended 31 December 2018, a 20.5% increase over the prior year.

ENDS

Enquiries

Investors

   Andrew Swift                                    +44 (0) 20 7960 2285 

Smith & Nephew

Media

   Charles Reynolds                             +44 (0) 1923 477314 

Smith & Nephew

About Smith & Nephew

Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine. Smith & Nephew has more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook.

(Forward-looking Statements)

(This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.)

(Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACQEAALXFLNNEFF

(END) Dow Jones Newswires

April 17, 2019 09:05 ET (13:05 GMT)

1 Year Smith & Nephew Chart

1 Year Smith & Nephew Chart

1 Month Smith & Nephew Chart

1 Month Smith & Nephew Chart
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190424 12:52:46